Israel based scientists found out that the rates of hospitalization and death due to COVID-19 were significantly lower among those who received nirmatrelvir in patients 65 years of age or older.
At the beginning of the surge of the omicron variant in January 2022, the Israeli authorities decided to pursue two lines of defense to protect the vulnerable and high-risk populations from severe Covid-19: a second booster dose and antiviral therapy.
- Read more about Nirmatrelvir effective in elder COVID-19 patients
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/nirmatrelvir-effective-in-elder-covid-19-patients
No comments:
Post a Comment